Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Rat Cd79b, His tagged

Cat.No. : Cd79b-8776R
Product Overview : Recombinant Rat Cd79b (O70153) (Met1-Asp158), fused with a polyhistidine tag at the C-terminus, was produced in Human Cell.
  • Specification
  • Gene Information
  • Related Products
Source : Human Cells
Species : Rat
Tag : His
Form : Lyophilized from a 0.2μm filtered solution of PBS, pH 7.4
Molecular Mass : The recombinant rat CD79B comprises 144 amino acids and predicts a molecular mass of 16.8 kDa. The apparent molecular mass of the recombinant protein is approximately 28 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Endotoxin : < 1.0 eu per μg of the protein as determined by the LAL method.
Stability : Samples are stable for up to twelve months from date of receipt at -70oC.
Storage : Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.
Gene Name : Cd79b Cd79b molecule, immunoglobulin-associated beta [ Rattus norvegicus ]
Official Symbol : Cd79b
Gene ID : 171055
mRNA Refseq : NM_133533
Protein Refseq : NP_598217

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
How does CD79B-targeted immunotherapy differ from traditional chemotherapy in treating B cell malignancies? 03/27/2021

CD79B-targeted immunotherapy aims to specifically target B cells, potentially reducing side effects compared to non-specific chemotherapy.

How does CD79B contribute to the development of personalized treatment strategies for B cell diseases? 01/12/2021

Analyzing CD79B expression helps tailor treatment plans, allowing for more personalized and effective approaches.

Can CD79B be used as a biomarker for minimal residual disease in B cell malignancies? 05/13/2018

Yes, monitoring CD79B levels can aid in detecting minimal residual disease, providing insights into treatment response.

Are there any challenges or limitations associated with relying on CD79B as a diagnostic marker? 03/02/2017

Variability in CD79B expression among different B cell disorders may pose challenges in its use as a standalone diagnostic marker.

Are there any clinical trials investigating the therapeutic potential of CD79B-targeted drugs? 01/22/2016

Yes, several clinical trials are exploring the efficacy of CD79B-targeted drugs in various B cell disorders.

Customer Reviews (3)

Write a review
Reviews
04/26/2023

    Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

    11/16/2021

      The CD79B protein comes highly recommended for its outstanding performance in ELISA assays.

      10/26/2018

        One notable advantage of the CD79B protein is the excellent technical support provided by its manufacturer.

        Ask a Question for All Cd79b Products

        Required fields are marked with *

        My Review for All Cd79b Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends